| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.1 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.1 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.072 | 0.1 |